一例男性转移性乳腺癌患者的18F-PSMA 1007摄取
一名72岁男性转移性乳腺癌患者因临床怀疑同步前列腺癌而行18F-PSMA 1007 PET/CT,前列腺内未见异常摄取灶,但左乳软组织病灶、转移淋巴结及骨骼病灶可见异常摄取,且较18F-FDG PET/CT检出更多骨病灶。本例提示18F-PSMA 1007或可用于男性转移性乳腺癌的显像。
要点
- 18F-PSMA 1007 PET/CT在前列腺内未见异常摄取灶。
- 左乳软组织病灶、转移淋巴结及骨骼病灶可见异常摄取。
- 较18F-FDG PET/CT,18F-PSMA 1007检出更多骨病灶。
核心结论
- 本例发现提示18F-PSMA 1007或可用于男性转移性乳腺癌的显像。
研究设计与样本
- 本文为个案报告,对象为一名72岁已知转移性乳腺癌的男性患者。
主要发现
- 18F-PSMA 1007 PET/CT示前列腺内无异常摄取灶,左乳软组织病灶、转移淋巴结及骨骼病灶可见异常摄取。
- 与18F-FDG PET/CT相比,18F-PSMA 1007显像检出更多骨病灶。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A 72-year-old man, who is known with a case of metastatic carcinoma of the breast, was referred for F-PMSA 1007 PET/CT with clinical suspicion of synchronous prostate cancer. F-PSMA 1007 PET/CT scan detected no abnormal tracer concentrating lesion in the prostate gland; however, abnormal tracer concentration was noted in soft tissue lesions in left breast, metastatic lymph nodes, and skeletal lesions. Compared with F-FDG PET/CT, more bone lesions were detected on F-PSMA 1007 imaging. The findings of our case open the possibility of imaging metastatic breast cancer with F-PSMA 1007 in men.
引用
- Marafi F, Sasikumar A, Alfeeli M, et al. 18F-PSMA 1007 Uptake in a Man With Metastatic Breast Cancer. Clin Nucl Med. 2020. PMID: 32332302. doi:10.1097/RLU.0000000000003013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。